{"id":70093,"date":"2026-08-26T18:16:17","date_gmt":"2026-08-26T18:16:17","guid":{"rendered":"https:\/\/www.europesays.com\/france\/70093\/"},"modified":"2026-08-26T18:16:17","modified_gmt":"2026-08-26T18:16:17","slug":"sanofi-boasts-a-dividend-yield-of-5-4-trades-below-9x-earnings-and-just-got-an-fda-win-are-income-investors-missing-a-rare-opportunity","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/france\/70093\/","title":{"rendered":"Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity?"},"content":{"rendered":"

For income investors, there’s a solid stock that pays a handsome dividend and, due to a recent decline in its share price, is trading at a bargain-basement price. I’m talking about Sanofi (SNY<\/a> -1.21%), the French multinational pharmaceutical that is focused on immunology, vaccines, and rare diseases.<\/p>\n

The stock pays a $0.61 quarterly dividend, yielding about 5.4% (the annual dividend divided by the share price). That’s a handsome yield by any measure. And when you factor in the impact of the company’s stock buybacks, that yield rises to near 11%. And the company has raised its dividend for 30 consecutive years, making it a member of the European Dividend Aristocrats\u00ae (a registered trademark of Standard & Poor’s Financial Services LLC).<\/p>\n

And yet, Sanofi’s share price is down about 6.5% this year. Part of that is because the drugmaker canceled several major late-stage programs, raising valid investor concerns about its drug pipeline. Does that spell opportunity now for investors? Let’s see.<\/p>\n

\"Sanofi<\/p>\n

Today’s Change<\/p>\n

(-1.21%) $-0.56<\/p>\n

Current Price<\/p>\n

$45.47<\/p>\n

Key Data Points<\/p>\n

Market Cap<\/p>\n

$110BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.<\/p>\n

Day’s Range<\/p>\n

$45.45 – $46.04<\/p>\n

52wk Range<\/p>\n

$40.89 – $52.68<\/p>\n

Volume<\/p>\n

1M<\/p>\n

Avg Vol<\/p>\n

3.3M<\/p>\n

Gross Margin<\/p>\n

66.29%<\/p>\n

Dividend Yield<\/p>\n

5.26%<\/p>\n

Sanofi beat revenue and earnings expectations in the most recent quarter<\/p>\n

But the company recently posted strong second-quarter results. It earned $1.22 a share on revenue of $13.48 billion, both of which beat analysts’ expectations. And sales of its blockbuster immunology drug, Dupixent, climbed 38% to 5.15 billion euros, surpassing 5 billion euros in a quarter for the first time. <\/p>\n

But investors considering Sanofi’s shares need to look forward, not back. And the company just got some very good news: In July, the U.S. Food and Drug Administration (FDA) approved the company’s on-body injector for isatuximab, sold under the brand name Sarclisa, which treats multiple myeloma, a type of bone marrow and blood cancer. <\/p>\n

As a result, the stock has rebounded in recent weeks and is up about 6% so far in August.<\/p>\n

\"An<\/p>\n

Image source: Getty Images.<\/p>\n

Wall Street thinks it can continue to climb. The average analyst price target for the stock is $53.72, representing a nearly 18% gain from the current share price. Of the 10 analysts who follow the stock, five rate it a “Buy” and five a “Hold.”<\/p>\n

And the stock is inexpensive right now, trading at slightly more than nine times forward earnings. Consider that major drugmakers<\/a> like Eli Lilly (LLY<\/a> -3.31%), Merck (MRK<\/a> -1.79%), and Johnson & Johnson<\/a> (JNJ<\/a> -1.06%) are all trading at more than 20 times forward earnings.<\/p>\n

So, for investors looking for stocks trading cheaply relative to peers that deliver a strong dividend yield and have potential for future price appreciation, Sanofi right now checks all the boxes.<\/p>\n","protected":false},"excerpt":{"rendered":"For income investors, there’s a solid stock that pays a handsome dividend and, due to a recent decline…\n","protected":false},"author":2,"featured_media":70094,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12983],"tags":[13012],"class_list":["post-70093","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sanofi","tag-sanofi"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts\/70093","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/comments?post=70093"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts\/70093\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/media\/70094"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/media?parent=70093"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/categories?post=70093"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/tags?post=70093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}